Amivantamab
About
Therapy type: Targeted therapy
Therapy strategy: EGFR inhibition
Mappings
NCI Thesaurus: Amivantamab (ncit:C124993)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | EGFR Exon 20 (Insertion) | Non-Small Cell Lung Cancer | Amivantamab, Carboplatin, Pemetrexed | |
| Sensitivity (+) | EGFR Exon 20 (Insertion) | Non-Small Cell Lung Cancer | Amivantamab | |
| Sensitivity (+) | EGFR Exon 19 (Deletion) | Non-Small Cell Lung Cancer | Amivantamab, Lazertinib | |
| Sensitivity (+) | EGFR p.L858R | Non-Small Cell Lung Cancer | Amivantamab, Lazertinib | |
| Sensitivity (+) | EGFR Exon 19 (Deletion) | Non-Small Cell Lung Cancer | Amivantamab, Lazertinib | |
| Sensitivity (+) | EGFR p.L858R | Non-Small Cell Lung Cancer | Amivantamab, Lazertinib | |
| Sensitivity (+) | EGFR Exon 19 (Deletion) | Non-Small Cell Lung Cancer | Amivantamab, Carboplatin, Pemetrexed | |
| Sensitivity (+) | EGFR p.L858R | Non-Small Cell Lung Cancer | Amivantamab, Carboplatin, Pemetrexed | |
| Sensitivity (+) | EGFR Exon 20 (Insertion) | Non-Small Cell Lung Cancer | Amivantamab, Carboplatin, Pemetrexed | |
| Sensitivity (+) | EGFR Exon 20 (Insertion) | Non-Small Cell Lung Cancer | Amivantamab |